Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TT8DBY3)

• DTT Name: Angiotensin II receptor type-1 (AGTR1) DTT Info
• Gene Name: AGTR1

Molecule-Related Drug & Molecule List

16 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ANGIOTENSIN II	DMLWQ27	Increase blood pressure	BA04	Approved	[1]
Azilsartan	DMOIX5S	Hypertension	BA00-BA04	Approved	[2]
Candesartan	DMRK8OT	Chronic heart failure	BD1Z	Approved	[3]
Eprosartan	DM07K2I	Hypertension	BA00-BA04	Approved	[4]
Forasartan	DMRBJNZ	Hypertension	BA00-BA04	Approved	[5]
Irbesartan	DMTP1DC	Diabetic kidney disease	GB61.Z	Approved	[6]
Losartan	DM72JXH	Diabetic kidney disease	GB61.Z	Approved	[6]
Micardis telmisartan	DM3O6CY	Hypertension	BA00-BA04	Approved	[7]
Olmesartan medoxomil	DMWBHRY	High blood pressure	BA00	Approved	[8]
Saprisartan	DM4087K	Hypertension	BA00-BA04	Approved	[9]
SARALASIN	DMKS1DV	Hypertension	BA00-BA04	Approved	[10]
Saralasin Acetate	DMKZROL	Hypertension	BA00-BA04	Approved	[11]
Sparsentan	DMMP51W	IgA nephropathy	MF8Y	Approved	[12]
Tasosartan	DMM13DI	Hypertension	BA00-BA04	Approved	[13]
Telmisartan	DMS3GX2	Hypertension	BA00-BA04	Approved	[14]
Valsartan	DMREUQ6	Chronic heart failure	BD1Z	Approved	[6]

6 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Pratosartan	DMOMDXI	Hypertension	BA00-BA04	Phase 3	[15]
S-474474	DM408GM	Metabolic syndrome x	5C50-5D2Z	Phase 3	[16]
TAK-491	DMCF6SX	Hypertension	BA00-BA04	Phase 3	[2]
CL-329167	DMSF7WJ	Hypertension	BA00-BA04	Phase 2	[17]
TRV027	DMVX6H0	Heart failure	BD10-BD13	Phase 2	[18]
YM-358	DMS7609	Hypertension	BA00-BA04	Phase 2	[19]

14 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
KRH-594	DMIJ6FX	Hypertension	BA00-BA04	Discontinued in Phase 2	[20]
MILFASARTAN	DMTX97J	Hypertension	BA00-BA04	Discontinued in Phase 2	[21]
RIPISARTAN	DME5MGP	Hypertension	BA00-BA04	Discontinued in Phase 2	[22]
Zolasartan	DM9FQI0	Hypotension	BA20-BA21	Discontinued in Phase 2	[23]
TAK-591	DM25DB4	Hypertension	BA00-BA04	Discontinued in Phase 1	[24]
UR-7198	DMXN9Z5	Hypertension	BA00-BA04	Discontinued in Phase 1	[25]
A-81988	DM1GLIN	Hypertension	BA00-BA04	Terminated	[26]
CR-3834	DMTPDX7	Hypertension	BA00-BA04	Terminated	[27]
HELENALIN	DMMCI4H	N. A.	N. A.	Terminated	[28]
L-158809	DMQ4LDB	Hypertension	BA00-BA04	Terminated	[29]
L-159689	DM9JE7Y	Hypertension	BA00-BA04	Terminated	[12]
RS-66252	DMT5DH0	Alzheimer disease	8A20	Terminated	[30]
UP-275-22	DM37DOC	Hypertension	BA00-BA04	Terminated	[31]
XR-510	DMA13OD	Hypertension	BA00-BA04	Terminated	[32]

31 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
(E)-N-(3-iodoprop-2-enyl)-2beta-carbomethoxy-3beta-(4'-methylphenyl)n	DMW3RJL	Discovery agent	N.A.	Investigative	[33]
4-(2-Butyl-benzoimidazol-1-ylmethyl)-phenol	DM8HLEP	Discovery agent	N.A.	Investigative	[34]
4-hydroxy-1-methyl-4-(4-methylphenyl)-3-piperidyl 4-methylphenyl ketone	DMTZ9G3	Discovery agent	N.A.	Investigative	[35]
4-[(diphenylmethyl)amino]-2-phenylquinazoline	DMT1PM4	Discovery agent	N.A.	Investigative	[36]
5-butyl-methyl immidazole carboxylate 30	DM0VGCX	Discovery agent	N.A.	Investigative	[37]
5-oxo-1-2-4-oxadiazol biphenyl	DME62OQ	Discovery agent	N.A.	Investigative	[38]
angiotensin III	DMYK0Z9	Discovery agent	N.A.	Investigative	[31]
CGP-49870	DM5SATN	Discovery agent	N.A.	Investigative	[39]
CV-11194	DMEB0FX	Discovery agent	N.A.	Investigative	[40]
EXP3174	DMWIBFM	Discovery agent	N.A.	Investigative	[41]
GNF-PF-2307	DMP6DBX	Discovery agent	N.A.	Investigative	[28]
GNF-PF-2812	DMD1QOH	Discovery agent	N.A.	Investigative	[28]
GNF-PF-3832	DMIY79U	Discovery agent	N.A.	Investigative	[28]
INC-106	DM8E4HB	Artery stenosis	BD52	Investigative	[31]
L-159093	DMOX8JE	Discovery agent	N.A.	Investigative	[12]
L-162313	DMZOW96	Discovery agent	N.A.	Investigative	[42]
L-162782	DMWSP6H	Discovery agent	N.A.	Investigative	[42]
L-163,101	DMYC7AK	Discovery agent	N.A.	Investigative	[43]
LY301875	DM2HQ9O	Discovery agent	N.A.	Investigative	[44]
LY303336	DMY9WTE	Discovery agent	N.A.	Investigative	[44]
N,N`-bis-alkyl butylimmidazole 12b	DMNZKCL	Discovery agent	N.A.	Investigative	[45]
[125I]EXP985	DMEKGZS	Discovery agent	N.A.	Investigative	[46]
[3H]GBR12935	DMGQDLU	Discovery agent	N.A.	Investigative	[47]
[Bpa1]AngII	DMB78GP	Discovery agent	N.A.	Investigative	[1]
[Sar1,Bpa2]AngII	DM1HQ3D	Discovery agent	N.A.	Investigative	[1]
[Sar1,Bpa3]AngII	DMP64XH	Discovery agent	N.A.	Investigative	[1]
[Sar1,Bpa8]AngII	DMWC10R	Discovery agent	N.A.	Investigative	[1]
[Sar1,Tdf2]AngII	DM4AUFR	Discovery agent	N.A.	Investigative	[1]
[Sar1,Tdf3]AngII	DMWCS4Y	Discovery agent	N.A.	Investigative	[1]
[Sar1,Tdf8]AngII	DMTNGCW	Discovery agent	N.A.	Investigative	[1]
[Tdf1]AngII	DMN0BT3	Discovery agent	N.A.	Investigative	[1]

References

• [1] The amino-terminus of angiotensin II contacts several ectodomains of the angiotensin II receptor AT1. J Med Chem. 2010 Mar 11;53(5):2063-75.
• [2] 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
• [3] Candesartan: widening indications for this angiotensin II receptor blocker Expert Opin Pharmacother. 2009 Aug;10(12):1995-2007.
• [4] Clinical profile of eprosartan: a different angiotensin II receptor blocker. Cardiovasc Hematol Agents Med Chem. 2008 Oct;6(4):253-7.
• [5] Non-peptide angiotensin II receptor antagonists: chemical feature based pharmacophore identification. J Med Chem. 2003 Feb 27;46(5):716-26.
• [6] Radioligand binding assays: application of [(125)I]angiotensin II receptor binding. Methods Mol Biol. 2009;552:131-41.
• [7] The angiotensin II receptor antagonist telmisartan reduces urinary albumin excretion in patients with isolated systolic hypertension: results of a randomized, double-blind, placebo-controlled trial. J Hypertens. 2005 Nov;23(11):2055-61.
• [8] Mechanism of diastolic stiffening of the failing myocardium and its prevention by angiotensin receptor and calcium channel blockers. J Cardiovasc Pharmacol. 2009 Jul;54(1):47-56.
• [9] Pharmacological properties of angiotensin II receptor antagonists. Can J Cardiol. 1999 Nov;15 Suppl F:26F-8F.
• [10] Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity. J Med Chem. 2008 Jul 24;51(14):4150-69.
• [11] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [12] Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem. 2005 Oct 20;48(21):6523-43.
• [13] Tasosartan, enoltasosartan, and angiotensin II receptor blockade: the confounding role of protein binding. J Pharmacol Exp Ther. 2000 Nov;295(2):649-54.
• [14] Deletion of angiotensin II type I receptor reduces hepatic steatosis. J Hepatol. 2009 Jun;50(6):1226-35.
• [15] Clinical efficacy of a new angiotensin II type 1 receptor blocker, pratosartan, in hypertensive patients. Hypertens Res. 2008 Feb;31(2):281-7.
• [16] Clinical pipeline report, company report or official report of Shionogi (2011).
• [17] Distribution and function of cardiac angiotensin AT1- and AT2-receptor subtypes in hypertrophied rat hearts. Am J Physiol. 1994 Aug;267(2 Pt 2):H844-52.
• [18] First clinical experience with TRV027: pharmacokinetics and pharmacodynamics in healthy volunteers. J Clin Pharmacol. 2013 Sep;53(9):892-9.
• [19] Effects of YM358, an angiotensin II type 1 (AT1) receptor antagonist, and enalapril on blood pressure and vasoconstriction in two renal hypertension models. Biol Pharm Bull. 2000 Feb;23(2):174-81.
• [20] Binding of KRH-594, an antagonist of the angiotensin II type 1 receptor, to cloned human and rat angiotensin II receptors. Fundam Clin Pharmacol. 2002 Aug;16(4):317-23.
• [21] Dual action molecules: bioassays of combined novel antioxidants and angiotensin II receptor antagonists. Eur J Pharmacol. 2012 Nov 15;695(1-3):96-103.
• [22] In vitro pharmacological characterization of UP 269-6, a novel nonpeptide angiotensin II receptor antagonist. Fundam Clin Pharmacol. 1995;9(2):119-28.
• [23] Azilsartan: a newly approved angiotensin II receptor blocker. Cardiol Rev. 2011 Nov-Dec;19(6):300-4.
• [24] Clinical pipeline report, company report or official report of Takeda (2009).
• [25] Pharmacologic profile of UR-7247, an orally active angiotensin II AT1 receptor antagonist, in healthy volunteers. p6. J Cardiovasc Pharmacol. 2000 Mar;35(3):383-9.
• [26] [3H]A-81988, a potent, selective, competitive antagonist radioligand for angiotensin AT1 receptors. Eur J Pharmacol. 1994 Mar 15;267(1):49-54.
• [27] Pharmacokinetic study of a new angiotensin-AT1 antagonist by HPLC. J Pharm Biomed Anal. 2008 Sep 29;48(2):422-7.
• [28] In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
• [29] Characterization of the binding of [3H]L-158,809: a new potent and selective nonpeptide angiotensin II receptor (AT1) antagonist radioligand. Mol Pharmacol. 1992 Dec;42(6):1077-82.
• [30] Virtual Screening in Drug Discovery, Juan Alvarez Brian Shoichet. Page(218).
• [31] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 34).
• [32] Pharmacology of XR510, a potent orally active nonpeptide angiotensin II AT1 receptor antagonist with high affinity for the AT2 receptor subtype. J Cardiovasc Pharmacol. 1995 Sep;26(3):354-62.
• [33] Pharmacological characterization of (E)-N-(3-iodoprop-2-enyl)-2beta-carbomethoxy-3beta-(4'-methylphenyl)n ortropane as a selective and potent inhibitor of the neuronal dopamine transporter. J Pharmacol Exp Ther. 1999 Nov;291(2):648-54.
• [34] Discovery and development of aryl-fused imidazole-based angiotensin II antagonists, Bioorg. Med. Chem. Lett. 4(1):213-218 (1994).
• [35] Discovery of a novel dopamine transporter inhibitor, 4-hydroxy-1-methyl-4-(4-methylphenyl)-3-piperidyl 4-methylphenyl ketone, as a potential cocaine antagonist through 3D-database pharmacophore searching. Molecular modeling, structure-activity relationships, and behavioral pharmacological studies. J Med Chem. 2000 Feb 10;43(3):351-60.
• [36] Identification of a novel partial inhibitor of dopamine transporter among 4-substituted 2-phenylquinazolines. Bioorg Med Chem Lett. 2002 Aug 19;12(16):2225-8.
• [37] The discovery of new potent non-peptide Angiotensin II AT1 receptor blockers: a concise synthesis, molecular docking studies and biological evaluation of N-substituted 5-butylimidazole derivatives. Eur J Med Chem. 2012 Sep;55:358-74.
• [38] Synthesis and biological evaluation of novel potent angiotensin II receptor antagonists with anti-hypertension effect. Bioorg Med Chem. 2012 Apr 15;20(8):2747-61.
• [39] Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and AT1 receptor antagonists
• [40] Synthesis and angiotensin II receptor antagonistic activities of benzimidazole derivatives bearing acidic heterocycles as novel tetrazole bioisoste... J Med Chem. 1996 Dec 20;39(26):5228-35.
• [41] Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev. 1993 Jun;45(2):205-51.
• [42] Selective angiotensin II AT2 receptor agonists: Benzamide structure-activity relationships. Bioorg Med Chem. 2008 Jul 15;16(14):6841-9.
• [43] Structural model of antagonist and agonist binding to the angiotensin II, AT1 subtype, G protein coupled receptor. Chem Biol. 1994 Dec;1(4):211-21.
• [44] Inhibition of angiotensin II-induced inositol phosphate production by triacid nonpeptide antagonists in CHO cells expressing human AT1 receptors. Pharm Res. 2000 Dec;17(12):1482-8.
• [45] Rational design, efficient syntheses and biological evaluation of N,N'-symmetrically bis-substituted butylimidazole analogs as a new class of potent Angiotensin II receptor blockers. Eur J Med Chem. 2013 Apr;62:352-70.
• [46] [125I]EXP985: a highly potent and specific nonpeptide radioligand antagonist for the AT1 angiotensin receptor. Biochem Biophys Res Commun. 1992 Nov 16;188(3):1030-9.
• [47] Specific binding of 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenyl propyl) piperazine (GBR-12935), an inhibitor of the dopamine transporter, to human CYP2D6. Biochem Pharmacol. 1997 Jun 15;53(12):1937-9.